How Eli Lilly is Diversifying and Engaging Patients Using Decentralized Clinical Trial (DCT) Capabilities

A graduate of Butler University College of Pharmacy & Health Sciences, Craig Davenport has worked for Eli Lilly and Company for over 30 years. He is responsible for Lilly’s global Site Engagement organization. This strategic function selects and manages investigators for Lilly’s global portfolio of clinical trials. Mr Davenport recently returned to the US from China where for 4 years he led planning and execution of the clinical research supporting approval new medicines in China.Over his career he has held several other positions including Senior Director of Clinical Project Management where he led the organization that provides trial management and project management oversight to all of Lilly’s late phase clinical research. From 2003 through 2007, he led R&D activities for Lilly’s Japan affiliate. As Managing Executive Officer & Director of Drug Development for Eli Lilly Japan K. K. his responsibilities spanned project management, regulatory affairs, and domestic CM&C activities. He chaired the Japan research & development portfolio management committee, project governance committee, and supervised R&D Six Sigma activities.  Prior to moving to Japan, Mr Davenport was Chief Operations Officer on the Cialisä Product Team during which time the team was chosen as Product Team of the Year. Mr Davenport began his career with Eli Lilly in anti-infectives clinical research.Mr Davenport received the Lilly Research Laboratories President’s Award, the Excellence in Alliance Practice Award, and was one of twelve employees selected to serve on the first Lilly President’s Council.

Marilyn Metcalf, PhD, is the newly appointed Patient Engagement Vaccines Lead at GSK. She is excited to build partnerships promoting health and preventing disease. She co-chaired US Patients as Partners in 2020 and 2021; co-chaired the National Academies of Sciences, Engineering and Medicine Science of Patient Input Action Collaborative workshop; and is a lead author of CIOMS Working Group XI’s guidance for patient involvement in the development and safe use of medicines. Previously she was Family Health International’s project director of the NIH master contract for HIV vaccine research, was the head of GSK’s international Decision Sciences team, led Centocor’s Decision Sciences and R&D Portfolio Management team, led GSK’s Benefit Risk Evaluation team, was the head of GSK’s Pharmacovigilance Centre of Innovation and led GSK’s patient engagement in Oncology. She began her current role in January 2023.